Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?

Danaher Corporation DHR is scheduled to release fourth-quarter 2025 results on Jan. 28, before market open.The Zacks Consensus Estimate for revenues is pegged at $6.79 billion, which indicates an increase of 3.9% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $2.15 per share, which has increased a penny in the past 30 days. The estimate indicates an increase of 0.5% from the figure reported in the year-ago quarter. The company’s bottom line surpassed the Zacks Consensus Estimate in three of the preceding four quarters while missing the mark in one, the average beat being 8.7%.Let’s see how things have shaped up for Danaher this earnings season.Key Factors and Estimates for Q4Strength in the bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in Western Europe, is expected to have aided the Biotechnology segment. The segment’s performance is also likely to have benefited from solid demand from pharmaceutical customers for monoclonal antibodies (mAbs). For the fourth quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $2.02 billion, indicating a 7.9% rise from the year-ago reported number.Solid momentum in the clinical diagnostics businesses, driven by an increase in demand for non-respiratory disease tests, is expected to drive the Diagnostics segment’s results. Solid growth in the Beckman Colter Diagnostics unit is also likely to have boded well. For the fourth quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $2.71 billion, indicating a 2.6% rise from the year-ago reported number.Solid momentum in the flow cytometry and lab automation solutions business is likely to have boosted the performance of the Life Sciences segment in the quarter. For the fourth quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $2.06 billion, indicating a 1.2% rise from the year-ago reported number.Danaher acquired Abcam plc, a global supplier of protein consumables, in December 2023, which expanded the Life Sciences segment. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio are expected to have helped the company solve some pertinent healthcare challenges.However, DHR has been witnessing escalating cost of sales and SG&A expenses, which are likely to weigh on its bottom-line results. Also, the company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability.Danaher Corporation Price and EPS Surprise Danaher Corporation price-eps-surprise | Danaher Corporation QuoteEarnings WhispersOur proven model predicts an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here, as elaborated below. Earnings ESP: DHR has an Earnings ESP of +1.73% as the Most Accurate Estimate is pegged at $2.19 per share, which is higher than the Zacks Consensus Estimate of $2.15. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.Zacks Rank: DHR currently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.Other Stocks to ConsiderHere are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.Hologic, Inc. HOLX has an Earnings ESP of +1.97% and a Zacks Rank of 2 at present. The company is slated to release first-quarter fiscal 2026 (ended December 2025) results on Jan. 29.Hologic’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 1.9%.Cardinal Health, Inc. CAH has an Earnings ESP of +2.30% and a Zacks Rank of 2 at present. The company is scheduled to release fourth-quarter 2025 results on Feb. 5.Cardinal’s earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 9.4%.DexCom, Inc. DXCM has an Earnings ESP of +4.91% and a Zacks Rank of 3 at present. The company is slated to release fourth-quarter 2025 results on Feb. 12.DexCom’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 0.2%.Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Danaher Corporation (DHR): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks